Purpose
We developed simulation and modeling methods to predict the in vivo pharmacokinetic profiles of acyclovir, following escalating oral doses of valacyclovir, in wildtype and Pept1knockout mice. We also quantitated the contribution of specific intestinal segments in the absorption of valacyclovir in these mice.